Objective:To investigate the clinical significance and regulatory molecular mechanism of the circular RNA(circRNA)hsa_circ_0001445 in postmenopausal osteoporosis(PMOP).Methods:RNA was extracted from clinically collected blood samples, and the expression of circRNA hsa_circ_0001445 was detected by quantitative real-time PCR(qRT-PCR). Luciferase reporter gene analysis and RNA pull-down experiments were performed to investigate the interaction between two genes.Results:Compared with healthy controls, the plasma circRNA hsa_circ_0001445 in PMOP patients was down regulated( P<0.001). The circRNA hsa_circ_0001445 distinguished PMOP patients from healthy controls with high sensitivity and specificity.The area under the ROC curve(AUC)was 0.9654(95% CI: 0.9361-0.9947, P<0.001), and the sensitivity was 94.0%, while the specificity was 88.0%.The circRNA hsa_circ_0001445 promoted the osteogenic differentiation and inhibited the adipogenic differentiation of hBMSCs.The circRNA hsa_circ_0001445 can directly bind to miR-127-5p. Conclusions:Plasma level of the circRNA hsa_circ_0001445 is a potential diagnostic biomarker of PMOP and regulates the balance between osteogenesis and adipogenesis in hBMSCs by sponging miR-127-5p.

Objective:To investigate the association between fasting blood glucose levels and the risk of early vascular aging(EVA).Methods:The basic information, medical history, and laboratory results of 695 individuals who underwent health check-up at the Physical Examination Center of the First People′s Hospital of Changzhou from January 2020 to March 2021 were retrospectively analyzed.Results:A total of 695 healthy individuals were included in the study, among whom there were 249 cases of EVA and 446 cases of non-EVA. Compared to the non-EVA group, the EVA group showed significant differences in age, gender, triglycerides, high density lipoprotein-cholesterol(HDL-C), fasting blood glucose, left brachial-ankle pulse wave velocity(L-baPWV), right brachial-ankle pulse wave velocity(R-baPWV), systolic blood pressure, and diastolic blood pressure(all P<0.01). All participants were divided into three groups( T1, T2, T3) based on fasting blood glucose levels. As fasting blood glucose levels increased, body mass index, total cholesterol, triglycerides, HDL-C, low density lipoprotein-cholesterol, L-baPWV, R-baPWV, systolic blood pressure, diastolic blood pressure, and EVA indicators showed significant differences among the three groups(all P<0.05). Univariate logistic regression analysis showed that age, gender, triglycerides, HDL-C, systolic blood pressure, diastolic blood pressure, and fasting blood glucose levels were significantly associated with the occurrence of EVA(all P<0.05). For the continuous variable of fasting blood glucose, in the regression equations without correction, with preliminary correction, and with full correction of covariates, higher fasting blood glucose levels significantly increased the risk of EVA, with odds ratios( OR) of 2.249, 2.580, and 2.413, respectively(all P<0.001). Compared to the T1 group, the risk of EVA in the T2 group, after no correction, preliminary correction, and full correction of covariates, was 1.881, 2.040, and 1.972, respectively(all P<0.01). The risk of EVA in the T3 group, unadjusted, preliminary adjustment, and full adjustment of covariates, was 3.234, 3.733, and 3.410, respectively(all P<0.001). After adjusting for confounding factors, a linear relationship between fasting blood glucose levels and the occurrence of EVA was observed through smooth curve fitting. Conclusion:Elevated fasting blood glucose may increase the risk of developing EVA.